Description

TRAP-14 (SFLLRNPNDKYEPF) is a synthetic thrombin receptor agonist peptide.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C81H118N20O23—-[1]Sabo T, et al. Structure-activity studies of the thrombin receptor activating peptide. Biochem Biophys Res Commun. 1992 Oct 30;188(2):604-10.|[2]Maruyama Y, et al. Thrombin receptor agonist peptide decreases thrombomodulin activity in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1262-9.|[3]Sugama Y, et al. Thrombin receptor 14-amino acid peptide mediates endothelial hyperadhesivity and neutrophil adhesion by P-selectin-dependent mechanism. Circ Res. 1992 Oct;71(4):1015-9.–137339-65-2–1739.92–98.00–OC[C@H](N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N3[C@@H](CCC3)C(N[C@H](C(O)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CC=C(C=C5)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Cardiovascular Disease–H2O : ≥ 100 mg/mL–Thrombin—-Metabolic Enzyme/Protease–Peptides